Milestone Scientific (MLSS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting scheduled for July 16, 2024, to be held virtually, with voting on director elections and auditor ratification.
Record date for voting is May 28, 2024; 77,227,714 shares of common stock outstanding, each with one vote.
Forward-looking statements are included, with reference to risk factors in recent SEC filings.
Voting matters and shareholder proposals
Shareholders will vote on the election of seven directors and ratification of Marcum LLP as independent auditors for 2024.
No other proposals or business are anticipated, but proxies may vote on additional matters if they arise.
Board recommends voting in favor of all director nominees and auditor ratification.
Board of directors and corporate governance
Board consists of seven members, majority independent, with separate Chairman and CEO roles for governance balance.
Board met seven times in 2023; all members attended at least 75% of meetings.
Standing committees: Audit, Compensation, and Nominating, all comprised of independent directors.
Stockholders can communicate directly with the Board; director nominations by stockholders are considered.
Code of ethics and insider trading policy in place; clawback policy adopted for excess compensation.
Latest events from Milestone Scientific
- Q2 net income turned positive on a $2M NOL sale, with strong e-commerce and margin gains.MLSS
Q2 20241 Feb 2026 - Expanding into the $2B epidural market with patented tech, strong margins, and new Medicare coverage.MLSS
Lytham Partners Fall 2024 Investor Conference20 Jan 2026 - Commercialization accelerates with Medicare pricing, new partnerships, and strong clinical impact.MLSS
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Q3 revenue up 22% with strong dental growth, regulatory wins, and improved net loss.MLSS
Q3 202413 Jan 2026 - Q2 2025 revenue up 25% year-over-year, led by dental sales, but liquidity risks persist.MLSS
Q2 202523 Nov 2025 - Q3 2025 saw $2.4M revenue, lower expenses, and improved net loss amid ongoing financial risks.MLSS
Q3 202514 Nov 2025 - Shareholders to vote on board elections, share increase, and auditor ratification at the annual meeting.MLSS
Proxy Filing12 Nov 2025 - 2024 net sales fell to $8.6M with a $4.7M net loss, but new funding and approvals support operations.MLSS
Q4 20249 Jun 2025 - Net loss widened to $2.0M in Q1 2025 as higher expenses offset stable revenue.MLSS
Q1 20256 Jun 2025